Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research

M. Klanova, T. Soukup, R. Jaksa, J. Molinsky, L. Lateckova, BC. Maswabi, D. Prukova, J. Brezinova, K. Michalova, P. Vockova, F. Hernandez-Ilizaliturri, V. Kulvait, J. Zivny, M. Vokurka, E. Necas, M. Trneny, P. Klener,

. 2014 ; 94 (7) : 806-817.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc14074193

Grant support
NT13201 MZ0 CEP Register

Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) associated with poor prognosis. Animal models of MCL are scarce. We established and characterized various in vivo models of metastatic human MCL by tail vein injection of either primary cells isolated from patients with MCL or established MCL cell lines (Jeko-1, Mino, Rec-1, Hbl-2, and Granta-519) into immunodeficient NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ mice. MCL infiltration was assessed with immunohistochemistry (tissues) and flow cytometry (peripheral blood). Engraftment of primary MCL cells was observed in 7 out of 12 patient samples. The pattern of engraftment of primary MCL cells varied from isolated involvement of the spleen to multiorgan infiltration. On the other hand, tumor engraftment was achieved in all five MCL cell lines used and lymphoma involvement of murine bone marrow, spleen, liver, and brain was observed. Overall survival of xenografted mice ranged from 22 ± 1 to 54 ± 3 days depending on the cell line used. Subsequently, we compared the gene expression profile (GEP) and phenotype of the engrafted MCL cells compared with the original in vitro growing cell lines (controls). We demonstrated that engrafted MCL cells displayed complex changes of GEP, protein expression, and sensitivity to cytotoxic agents when compared with controls. We further demonstrated that our MCL mouse models could be used to test the therapeutic activity of systemic chemotherapy, monoclonal antibodies, or angiogenesis inhibitors. The characterization of MCL murine models is likely to aid in improving our knowledge in the disease biology and to assist scientists in the preclinical and clinical development of novel agents in relapsed/refractory MCL patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074193
003      
CZ-PrNML
005      
20191015135227.0
007      
ta
008      
141006s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/labinvest.2014.61 $2 doi
035    __
$a (PubMed)24862967
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Klánová, Magdalena $u 1] First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic [2] First Department of Medicine, Clinical Department of Hematology of the General University Hospital, Charles University in Prague, Prague, Czech Republic. $7 _AN066006
245    10
$a Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research / $c M. Klanova, T. Soukup, R. Jaksa, J. Molinsky, L. Lateckova, BC. Maswabi, D. Prukova, J. Brezinova, K. Michalova, P. Vockova, F. Hernandez-Ilizaliturri, V. Kulvait, J. Zivny, M. Vokurka, E. Necas, M. Trneny, P. Klener,
520    9_
$a Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) associated with poor prognosis. Animal models of MCL are scarce. We established and characterized various in vivo models of metastatic human MCL by tail vein injection of either primary cells isolated from patients with MCL or established MCL cell lines (Jeko-1, Mino, Rec-1, Hbl-2, and Granta-519) into immunodeficient NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ mice. MCL infiltration was assessed with immunohistochemistry (tissues) and flow cytometry (peripheral blood). Engraftment of primary MCL cells was observed in 7 out of 12 patient samples. The pattern of engraftment of primary MCL cells varied from isolated involvement of the spleen to multiorgan infiltration. On the other hand, tumor engraftment was achieved in all five MCL cell lines used and lymphoma involvement of murine bone marrow, spleen, liver, and brain was observed. Overall survival of xenografted mice ranged from 22 ± 1 to 54 ± 3 days depending on the cell line used. Subsequently, we compared the gene expression profile (GEP) and phenotype of the engrafted MCL cells compared with the original in vitro growing cell lines (controls). We demonstrated that engrafted MCL cells displayed complex changes of GEP, protein expression, and sensitivity to cytotoxic agents when compared with controls. We further demonstrated that our MCL mouse models could be used to test the therapeutic activity of systemic chemotherapy, monoclonal antibodies, or angiogenesis inhibitors. The characterization of MCL murine models is likely to aid in improving our knowledge in the disease biology and to assist scientists in the preclinical and clinical development of novel agents in relapsed/refractory MCL patients.
650    _2
$a senioři $7 D000368
650    _2
$a zvířata $7 D000818
650    _2
$a kostní dřeň $x metabolismus $7 D001853
650    _2
$a mozek $x metabolismus $7 D001921
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ženské pohlaví $7 D005260
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a imunofenotypizace $7 D016130
650    _2
$a receptory interleukinů - společná gama-podjednotka $x nedostatek $x genetika $7 D053631
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a játra $x metabolismus $7 D008099
650    _2
$a lymfom z plášťových buněk $x farmakoterapie $x genetika $x metabolismus $7 D020522
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední NOD $7 D016688
650    _2
$a myši knockoutované $7 D018345
650    _2
$a myši SCID $7 D016513
650    _2
$a lidé středního věku $7 D008875
650    _2
$a slezina $x metabolismus $7 D013154
650    _2
$a transkriptom $x genetika $7 D059467
650    _2
$a transplantace heterologní $7 D014183
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Soukup, Tomáš, $u Medical Faculty Hradec Kralove, Institute of Histology and Embryology, Charles University, Prague, Czech Republic. $d 1980- $7 xx0036274
700    1_
$a Jakša, Radek $u First Faculty of Medicine, Institute of Pathology, Charles University in Prague. $7 xx026017301
700    1_
$a Molinský, Jan $u 1] First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic [2] First Department of Medicine, Clinical Department of Hematology of the General University Hospital, Charles University in Prague, Prague, Czech Republic. $7 xx0230618
700    1_
$a Latečková, Lucie $u 1] First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic [2] First Department of Medicine, Clinical Department of Hematology of the General University Hospital, Charles University in Prague, Prague, Czech Republic. $7 _AN078920
700    1_
$a Maswabi, Bokang C L $u First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Prukova, Dana $u First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Březinová, Jana, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1958- $7 xx0046958
700    1_
$a Michalová, Kyra, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1942- $7 nlk19990073558
700    1_
$a Vockova, Petra $u 1] First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic [2] First Department of Medicine, Clinical Department of Hematology of the General University Hospital, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Hernandez-Ilizaliturri, Francisco $u Department of Medical Oncology and Immunology, Cancer Cell Center, Roswell Park Cancer Institute, Buffalo, NY, USA.
700    1_
$a Kulvait, Vojtech $u First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Živný, Jan $u First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic. $7 xx0115576
700    1_
$a Vokurka, Martin, $u First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic. $d 1962- $7 jn20001005320
700    1_
$a Nečas, Emanuel, $u First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic. $d 1943- $7 jk01082825
700    1_
$a Trněný, Marek, $u 1] First Department of Medicine, Clinical Department of Hematology of the General University Hospital, Charles University in Prague, Prague, Czech Republic [2] Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1960- $7 nlk20000083659
700    1_
$a Klener, Pavel, $u 1] First Faculty of Medicine, Institute of Pathological Physiology, Charles University in Prague, Prague, Czech Republic [2] First Department of Medicine, Clinical Department of Hematology of the General University Hospital, Charles University in Prague, Prague, Czech Republic. $d 1975- $7 xx0105452
773    0_
$w MED00003111 $t Laboratory investigation; a journal of technical methods and pathology $x 1530-0307 $g Roč. 94, č. 7 (2014), s. 806-817
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24862967 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20191015135652 $b ABA008
999    __
$a ok $b bmc $g 1042076 $s 873105
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 94 $c 7 $d 806-817 $i 1530-0307 $m Laboratory investigation $n Lab Invest $x MED00003111
GRA    __
$a NT13201 $p MZ0
LZP    __
$a Pubmed-20141006

Find record

Citation metrics

Archiving options